Frequency Therapeutics. has been granted a patent for compositions and methods aimed at treating disorders through the deamination of adenosine in mRNA. The patent includes a specific oligonucleotide structure featuring 2′-O-methyl-nucleotides, which plays a crucial role in the therapeutic process. GlobalData’s report on Frequency Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Frequency Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Frequency Therapeutics's grant share as of June 2024 was 11%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12031131B2 outlines a novel oligonucleotide structure characterized by specific nucleotide compositions and modifications. The oligonucleotide comprises a sequence defined by the formula [Am]-X1—X2—X3—[Bn], where A and B represent nucleotides, with at least 20% of the combined nucleotides being 2'-O-methyl-nucleotides. The claims detail various configurations of the nucleotides, including the presence of ribonucleotides, 2'-O—C1-C6 alkyl-nucleotides, and other modified nucleotides. The patent also specifies that the oligonucleotide can include phosphorothioate linkages and outlines the percentage of nucleotides that must contain a nucleobase, sugar, and internucleoside linkage, with claims ranging from 80% to 95%.
Additionally, the patent describes methods for utilizing the oligonucleotide in therapeutic applications, including the treatment of disorders such as alpha-1-antitrypsin deficiency. It also presents a method for deaminating an adenosine in mRNA by using the oligonucleotide, which can form a hybridized complex with mRNA, featuring a specific mismatch. The claims emphasize the versatility of the oligonucleotide in terms of its nucleotide composition and potential applications in gene therapy and molecular biology, highlighting its significance in addressing genetic disorders.
To know more about GlobalData’s detailed insights on Frequency Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
